Grant: Discovery Grants Program - Individual
University of Calgary
$70,000.00
Bioprocessing of human neural stem/progenitor cells for the treatment of Parkinson's disease
EF 2009-10
Résumé
The Research Proposal I am putting forward in this NSERC Discovery Grant Application is very much a discovery project based on the bioprocessing of a type of human brain cell (i.e. adult stem harvested from somatic tissue) that I am now convinced will play a critically important role in a planned international clinical trial on Parkinson's disease. The first part of this clinical trial (i.e. based on stem cell therapy) will treat about 100 patients via transplantation of primary human tissue harvested from the ventral mesencephalon (VM) region of the human brain. The second stage of the clinical trial will use human brain cells produced using the bioreactor technology platform developed in my laboratory at the University of Calgary. The approach is a cell restorative strategy that focuses on restoring lost function by replacing the degenerated dopamine (DA)-producing neurons (DAergic neurons) using a transplantation procedure developed by a neurosurgeon colleague, Dr. Ivar Mendez, for the treatment of Parkinson's disease (PD).
Specifically, I want to launch a new 4 part study on the expansion of human VM cells in bioreactors and eventually to enrich the cell population to an active type of neuron called A9 neurons that we now realize will play an essential role in increasing the success of the planned clinical trials. Preliminary experiments carried out on this problem in my laboratory have led me to the realization that this is an extremely difficult problem. However, having reviewed the literature data and our own preliminary data, I think that my Research Proposal has a very good chance of success in the short term since we have learned to avoid many pitfalls in tackling this problem. The proposed research strategies with human VM cells include examining - (1) hypoxic oxygen conditions, (2) role of calcium in cell growth media, (3) controlled conversion of the VM cells by exposure to inducing agents such as brain-derived neurotrophic factor (BDNF), dopamine, fibroblast growth factor (FGF)-8 and/or forskolin, and (4) genetic manipulation by transfection of the VM cells with developmental cues such as Wnt5a or overexpression of the genes that are likely to be involved in production of the DAergic neurons.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
6583-2009
Name nom
Behie, Leo
Department département
Chemical and Petroleum Engineering
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
70000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
4
Committee name en
Chem. & Metallurgical Eng.
Committee name fr
Génies chimique et métal.
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
5
Application title
Bioprocessing of human neural stem/progenitor cells for the treatment of Parkinson's disease
Keyword
NA
Application summary
The Research Proposal I am putting forward in this NSERC Discovery Grant Application is very much a discovery project based on the bioprocessing of a type of human brain cell (i.e. adult stem harvested from somatic tissue) that I am now convinced will play a critically important role in a planned international clinical trial on Parkinson's disease. The first part of this clinical trial (i.e. based on stem cell therapy) will treat about 100 patients via transplantation of primary human tissue harvested from the ventral mesencephalon (VM) region of the human brain. The second stage of the clinical trial will use human brain cells produced using the bioreactor technology platform developed in my laboratory at the University of Calgary. The approach is a cell restorative strategy that focuses on restoring lost function by replacing the degenerated dopamine (DA)-producing neurons (DAergic neurons) using a transplantation procedure developed by a neurosurgeon colleague, Dr. Ivar Mendez, for the treatment of Parkinson's disease (PD).
Specifically, I want to launch a new 4 part study on the expansion of human VM cells in bioreactors and eventually to enrich the cell population to an active type of neuron called A9 neurons that we now realize will play an essential role in increasing the success of the planned clinical trials. Preliminary experiments carried out on this problem in my laboratory have led me to the realization that this is an extremely difficult problem. However, having reviewed the literature data and our own preliminary data, I think that my Research Proposal has a very good chance of success in the short term since we have learned to avoid many pitfalls in tackling this problem. The proposed research strategies with human VM cells include examining - (1) hypoxic oxygen conditions, (2) role of calcium in cell growth media, (3) controlled conversion of the VM cells by exposure to inducing agents such as brain-derived neurotrophic factor (BDNF), dopamine, fibroblast growth factor (FGF)-8 and/or forskolin, and (4) genetic manipulation by transfection of the VM cells with developmental cues such as Wnt5a or overexpression of the genes that are likely to be involved in production of the DAergic neurons.